ClinicalTrials.gg
Active, not recruitingNCT07081633TREMENDOUS-2Updated Oct 13, 2026

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

A Phase 2 interventional study of Durvalumab and Tremelimumab in Hepatocellular Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing durvalumab in Carcinoma, Hepatocellular — 22 open to participants now, 32 under way, 4 of them phase 3. durvalumab · Carcinoma, Hepatocellular.

Enrollment
7th of 42
114 · median 37
Started
2025
with 6 others
Phase 2
28 of 42
15 open now
Primary completion
2026-11
later than 14 of 31 live
Registered
39th of 42
by date
Lead sponsor
7 of 42
AstraZeneca

Among the 42 studies testing durvalumab in Carcinoma, Hepatocellular, this one is the 7th largest by enrollment, is one of 7 that started in 2025, is one of 28 in phase 2, reaches primary completion later than 14 of the 31 other live ones, and was the 39th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

22 of the 42 studies testing durvalumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing durvalumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings.
  • Must not have received prior systemic therapy for unresectable HCC.
  • Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
  • Score class A.
  • performance status of 0 or 1 at enrollment.
  • At least 1 per RECSIT 1.1 guidelines

Exclusion criteria

Exclusion Criteria:

  • Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event () Grade ≥2 from previous anticancer therapy.
  • History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy.
  • ascites.
  • Patients with main portal vein thrombosis.
  • Active or prior documented GI bleeding.
  • Patient currently exhibits symptomatic or uncontrolled hypertension.
  • Patients co-infected with and , or co-infected with HBV and hepatitis D virus (HDV)
  • Uncontrolled intercurrent illness
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Single Arm

    Durvalumab and Tremelimumab with Lenvatinib

    Drug: Durvalumab · Drug: Tremelimumab · Combination Product: Lenvatinib

Interventions

  • Durvalumab IV (intravenous infusion)

    Also known as: MEDI4736

  • Tremelimumab IV (intravenous infusion)

  • Combination productLenvatinib

    Lenvatinib Oral

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) per RECIST 1.1

    Efficacy endpoint

    Time frame: From the date of first dose until the date of objective PD per RECIST 1.1 or death, whichever came first. It will be assessed when approximately 69 PFS events have occurred (60% maturity), approximately 8 months after the last patients dosed.

Secondary outcomes

  1. Grade ≥ 3 TRAE within 6 months after the initiation of study intervention

    safety endpoint

    Time frame: From first dose to 6 months after the initiation of study intervention

  2. Overall Survival (OS)

    Efficacy endpoint

    Time frame: From the date of the first dose of study intervention until death due to any cause. It will be assessed when approximately 69 OS events have occurred (60% maturity), approximately 24 months after last participant has been assigned to study intervention.

  3. Objective Response Rate (ORR) per RECIST 1.1

    Efficacy endpoint

    Time frame: From the date of the first dose of study intervention until the date of objective PD per RECIST 1.1. It is anticipated that this analysis will be performed approximately 8 months after the last patient has been assigned to study intervention.

  4. Disease Control Rate (DCR) per RECIST 1.1

    Efficacy endpoint

    Time frame: From the date of the first dose of study intervention until the date of objective PD per RECIST 1.1. It is anticipated that this analysis will be performed approximately 8 months after the last patient has been assigned to study intervention.

  5. Duration of response (DoR) per RECIST 1.1

    Efficacy endpoint

    Time frame: From the date of response until the date of objective PD per RECIST 1.1 or death, whichever came first. It is anticipated that this analysis will be performed approximately 8 months after the last patient dosed.

  6. Progression Free Survival (PFS) per mRECIST

    Efficacy endpoint

    Time frame: From the date of the first dose until the date of objective PD per mRECIST or death, whichever came first. It will be assessed when approximately 69 PFS events have occurred (60% maturity), approximately 8 months after the last patients dosed.

07

Study locations

23 sites
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Chengdu, 610078, China
  • Research Site
    Chongqing, 400016, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230022, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200438, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    New Territories, Hong Kong
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient- level data from AstraZeneca group of companies sponsored clinical trials via the request portal. Plan Description: All request will be evaluated as per the Az disclosure commitment: https://astrazenecaarouptrials.pharmacm.com/ST/Submission/Disclosure Yes. indicates that Az are accepting requests for IPD ,but this does not mean are quests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitment at made to the EFPIA Pharma Data Sharing Principles .For details of our timeline please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement(non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to a air access. For additional details. please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 15 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 23, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07081633
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Aug 5, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab · Lenvatinib

Start the discussion